Abstract
Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase (iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNA-binding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NO inhibits the proliferation of androgen receptor-positive prostate cancer cells significantly more efficiently than proliferation of androgen receptor-negative prostate cancer cells. In summary, our findings suggest that intratumoral iNOS activity favors development of prostate cancer cells that are able to proliferate androgen receptor-independently, thereby promoting prostate tumor progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aaltoma SH, Lipponen PK, Kosma VM . (2001). Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 21: 3101–3106.
Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC et al. (2002). Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143: 4599–4608.
Attardi BJ, Burgenson J, Hild SA, Reel JR . (2004). Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol Cell Endocrinol 222: 121–132.
Baltaci S, Orhan D, Gogus C, Turkolmez K, Tulunay O, Gogus O . (2001). Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 88: 100–103.
Berendji D, Kolb-Bachofen V, Meyer KL, Grapenthin O, Weber H, Wahn V et al. (1997). Nitric oxide mediates intracytoplasmic and intranuclear zinc release. FEBS Lett 405: 37–41.
Bradford MM . (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I et al. (2005). Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201: 1257–1268.
Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J . (1996). Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271: 6379–6388.
Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON et al. (1999). Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59: 5030–5036.
Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G et al. (2000). Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 82: 39–45.
Cronauer MV, Schulz WA, Ackermann R, Burchardt M . (2005). Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 26: 1033–1040.
Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M . (2004). Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23: 3541–3549.
Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R et al. (2003). The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling. Int J Oncol 23: 1095–1102.
Ekmekcioglu S, Tang CH, Grimm EA . (2005). NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 5: 103–115.
Feldman BJ, Feldman D . (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.
Garbán HJ, Bonavida B . (2001). Nitric oxide inhibits the transcription repressor yin-yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol 167: 75–81.
Garbán HJ, Marquez-Garbán DC, Pietras RJ, Ignarro LJ . (2005). Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci USA 102: 2632–2636.
Gast A, Neuschmid-Kaspar F, Klocker H, Cato AC . (1995). A single amino acid exchange abolishes dimerization of the androgen receptor and causes Reifenstein syndrome. Mol Cell Endocrinol 111: 93–98.
Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O et al. (1999). Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189: 224–229.
Grune T, Merker K, Sandig G, Davies KJ . (2003). Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 305: 709–718.
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A . (1996). Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129–135.
Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H et al. (1998). Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640–4645.
Hongo F, Garban H, Huerta-Yepez S, Vega M, Jazirehi AR, Mizutani Y et al. (2005). Inhibition of the transcription factor yin yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 336: 692–701.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809–1818.
Hrabie JA, Arnold EV, Citro ML, George C, Keefer LK . (2000). Reaction of nitric oxide at the beta-carbon of enamines. A new method of preparing compounds containing the diazeniumdiolate functional group. J Org Chem 65: 5745–5751.
Huguenin S, Fleury-Feith J, Kheuang L, Jaurand MC, Bolla M, Riffaud JP et al. (2004). Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 61: 132–141.
Keefer LK, Nims RW, Davies KM, Wink DA . (1996). ‘NONOates’ (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 268: 281–293.
Kleinert H, Wallerath T, Fritz G, Ihrig-Biedeert I, Rodriguez-Pascual F, Geller DA et al. (1998). Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-kB-signaling pathways. Br J Pharmacol 125: 193–201.
Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K . (1998). Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82: 1897–1903.
Kröncke KD, Carlberg C . (2000). Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide. FASEB J 14: 166–173.
Kröncke KD, Fehsel K, Schmidt T, Zenke FT, Dasting I, Wesener JR et al. (1994). Nitric oxide destroys zinc–sulfur clusters inducing zinc release from metallothionein and inhibition of the zinc finger-type yeast transcription activator LAC9. Biochem Biophys Res Commun 200: 1105–1110.
Kröncke KD, Haase H, Beyersmann D, Kolb-Bachofen V, Hayer-Hartl MK . (2001). Nitric oxide inhibits the cochaperone activity of the RING finger-like protein DnaJ. Nitric Oxide 5: 289–295.
Kröncke KD, Suschek CV, Kolb-Bachofen V . (2000). Implications of inducible nitric oxide synthase expression and enzyme activity. Antioxid Redox Signal 2: 585–605.
Le X, Wei D, Huang S, Lancaster Jr JR, Xie K . (2005). Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci USA 102: 8758–8763.
Marth C, Muller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W et al. (1990). Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50: 7037–7041.
Michalaki V, Syrigos K, Charles P, Waxman J . (2004). Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312–2316.
Mossmann T . (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55–62.
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB . (2004). The role of inflammation in the pathogenesis of prostate cancer. J Urol 172: S6–S11.
Nienhaus GU, Nienhaus K, Hölzle A, Ivanchenko S, Renzi F, Oswald F et al. (2005). Photoconvertible fluorescent protein EosFP – biophysical properties and cell biology applications. Photochem Photobiol 82: 351–358.
Olson MV, Lee J, Zhang F, Wang A, Dong Z . (2006). Inducible nitric oxide synthase activity is essential for inhibition of prostatic tumor growth by interferon-beta gene therapy. Cancer Gene Ther 13: 676–685.
Park JG, Oie HK, Sugarbaker PH, Henslee JG, Chen TR, Johnson BE et al. (1987). Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 47: 6710–6718.
Pearce LL, Gandley RE, Han W, Wasserloos K, Stitt M, Kanai AJ et al. (2000). Role of metallothionein in nitric oxide signaling as revealed by a green fluorescent fusion protein. Proc Natl Acad Sci USA 97: 477–482.
Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK . (2004). Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 172: 338–344.
Rudeck M, Volk T, Sitte N, Grune T . (2000). Ferritin oxidation in vitro: implication of iron release and degradation by the 20S proteasome. IUBMB Life 49: 451–456.
Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS et al. (1999). A new human prostate carcinoma cell line, 22Rv1. In vitro Cell Dev Biol Anim 35: 403–409.
Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF . (1978). Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274–281.
Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF et al. (2002). Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606–6614.
Thomsen LL, Miles DW . (1998). Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17: 107–118.
Wang J, Torbenson M, Wang Q, Ro JY, Becich M . (2003). Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol 21: 117–122.
Wiedenmann J, Ivanchenko S, Oswald F, Schmitt F, Röcker C, Salih A et al. (2004). EosFP, a fluorescent marker protein with UV-inducible green-to-red fluorescence conversion. Proc Natl Acad Sci USA 101: 15905–15910.
Acknowledgements
We thank Professor Dr KD Spindler for helpful suggestions. Supported by research grants from the Deutsche Forschungsgemeinschaft (SFB 503/B11 to KDK), the Doktor Robert Pfleger-Stiftung (to MB), and Vaincre le Cancer, Lions Club, Luxembourg (to MVC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cronauer, M., Ince, Y., Engers, R. et al. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 26, 1875–1884 (2007). https://doi.org/10.1038/sj.onc.1209984
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209984
Keywords
This article is cited by
-
Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
Nature Communications (2023)
-
The probable destructive mechanisms behind COVID-19 on male reproduction system and fertility
Journal of Assisted Reproduction and Genetics (2021)
-
Sex differences in COVID-19: the role of androgens in disease severity and progression
Endocrine (2021)
-
JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells
BMC Cancer (2017)
-
Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells
Cell Death & Disease (2014)